PO.BCS02.04 · 生物信息与计算
多期相CT扫描的自动对比期相分类
Automatic contrast phase classification of polyphasic CT scans
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
对比期相是指CT扫描期间静脉注射对比剂后血管、组织或器官强化的不同阶段。对比期相有助于将异常病灶与正常组织区分开来,其中病灶根据疾病表现为乏血供或富血供。因此,根据具体病理选择合适的期相对于准确检测、有意义的诊断解读、临床工作流程和稳健的定量分析至关重要。然而,在许多多期相CT扫描中,期相信息在元数据中缺失。
本研究提出了一种全自动流程,利用基于器官的影像特征预测CT扫描的对比期相。我们的方法有以下新颖贡献:(1)聚焦于有限的一组器官(主动脉、门静脉、肾脏),减少对广泛器官覆盖的依赖。这对于视野各异、许多器官可能缺失的扫描很有用。(2)引入源自一阶PyRadiomic统计量的工程化特征,量化器官间关系以捕捉期相特异性的强度模式。
我们的流程可区分非对比扫描和所有三个主要对比期相:动脉期、门静脉期、延迟期。使用TotalSegmentator(一种最先进的CT扫描分割深度学习算法)对主动脉、门静脉/脾静脉和肾脏进行自动分割。对于每个器官掩膜,使用PyRadiomics提取一组全面的一阶统计特征,包括均值、中位数、最小值、最大值、标准差、偏度、峰度、能量和熵,以捕捉强度分布。创建了反映器官间平均和最大强度差异的工程化特征,以及所有三个器官的总平均强度,以更好地区分期相。
该模型在TOPAZ-1 III期胆道癌试验数据集上训练和验证。TOPAZ-1包含1418次CT基线扫描(447次门静脉期、396次动脉期、323次非对比、252次延迟期),由一名具有八年经验的放射科医师标注。为进行分类,开发了一个随机森林分类器。分类实现了0.97的总体准确率,加权平均精确率、召回率和f1分数均为0.97。各期相的精确率、召回率和f1分数均超过0.93。分析表明,工程化特征显示动脉期以更亮的主动脉为特征,静脉期以更亮的门静脉为特征,延迟期以肾脏强度增加为特征,非对比扫描以相对于其他扫描的总体强度较低为特征。这些模式与放射科医师的预期一致,并支持模型的可解释性。
通过聚焦于最能指示期相差异的器官和特征,该流程产生了一个简单且可解释的模型,实现了准确的多期相CT期相识别。
查看英文原文 English abstract
Contrast phases refer to the different stages of blood vessel, tissue, or organ enhancement following the administration of an intravenous contrast agent during CT scans. Contrast phases help distinguish abnormal lesions from normal tissue, where lesions appear hypo- or hyper-vascular, depending on the disease. Therefore, selecting the appropriate phase based on the specific pathology is crucial for accurate detection, meaningful diagnostic interpretation, clinical workflows, and robust quantitative analysis. However, in many polyphasic CT scans, information about phases is missing from the metadata.
This study presents a fully automated pipeline to predict the contrast phase of CT scans, using organ-based image features. Our approach has the following novel contributions: (1) Focuses on a limited set of organs (aorta, portal vein, kidney), reducing reliance on extensive organ coverage. This is useful for scans with varying field-of-view where many organs may be absent. (2) Introduces engineered features derived from first-order PyRadiomic statistics, quantifying inter-organ relationships to capture phase-specific intensity patterns.
Our pipeline distinguishes non-contrast scans and all three major contrast phases: arterial, portal venous, delayed. Automated segmentation of the aorta, portal vein/splenic vein, and kidneys is performed using TotalSegmentator, a state-of-the-art deep learning algorithm for CT scan segmentation. For each organ mask, a comprehensive set of first-order statistical features, including mean, median, minimum, maximum, standard deviation, skewness, kurtosis, energy, and entropy, is extracted with PyRadiomics to capture intensity distributions. Engineered features reflecting the mean and maximum intensity differences between organs are created, along with the total mean intensity of all three organs, to better distinguish phases.
The model was trained and validated on the TOPAZ-1 phase 3 biliary tract cancer trial dataset. TOPAZ-1 comprised of 1418 CT baseline scans (447 portal venous, 396 arterial, 323 non-contrast, 252 delayed) annotated by a radiologist with eight years of experience. For classification, a random forest classifier was developed. Classification achieved an overall accuracy of 0.97, with weighted average precision, recall, and f1-score all at 0.97. Per-phase precision, recall and f1-score all exceed 0.93. On analysis, the engineered features indicate the arterial phase is characterized by a brighter aorta, the venous phase by a brighter portal vein, the delayed phase by increased renal intensity, and non-contrast scans by lower overall intensity relative to the other scans. These patterns align with radiologist expectations and support the model's interpretability.
By focusing on organs and features that are most indicative of phase differences, the pipeline yields a simple and interpretable model that achieves accurate polyphasic CT phase identification.
利益披露 Disclosure
G. Hughes,
Astrazeneca UK Independent Contractor.
M. Patwari,
Astrazeneca UK Employment.
Y. Wei,
Astrazeneca UK Employment.
M. Parker,
Astrazeneca UK Independent Contractor.
J. Parkin,
Astrazeneca UK Independent Contractor.
Z. Zhang,
Astrazeneca US Employment.
A. Filippov,
Astrazeneca US Employment.